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Texas consortium is recruit
ing people at high risk of
cancer for research studies.
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What is the link between
viral infection and the
development of lymphoma?
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Researchers Focus on Bioimmunotherap
for Treatment of Non-Hodgkin's Lymphomas

by Beth Notzon

he sheer number of non-Hodgkin's lymphomas-about

30 in all-has always presenced a complex challenge

to researchers. Whether they are indolent and grow

slowly, like follicular lymphoma, or are aggressive, fast

growing tumors such as Burkicc's lymphoma, all are serious cancers.
Now the incidence of non-Hodgkin's lymphoma, already the fifth
most common cancer in the United States, is on the rise and so is

the pressure on researchers to develop better treatments and more
sensitive diagnostic techniques for this diverse group of tumors.
(Continued on next page)

�ocametoM.D.
�. speaks with
Dr. Fernando Cabanillas (right),
chairman of the Department of Lymphoma
and Myeloma, as Dr. Javier Garcia
Conde, a visiting physician from Spain,
looks on. Researchers at M. D. Anderson
are investigating molecular therapies
to treat patients with non-Hodgkin's
lymphomas.
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Karen Copeland, the senior genetic counselor in the Clinical Cancer Genetics Program
at M. D. Anderson, explains how genetic traits are passed on in families . Copeland
counsels participants in the Texas Cancer Genetics Consortium, which is part of a nation
wide effort led /yy the National Cancer Institute tO learn more about genetic susceptibility
t.o cancer and how best to integrate that knowledge into patient care.
population for their studies.
So far the Texas network has recruited
about 850 individuals who are at high
risk for the development of inherited
cancers, according to Karen Copeland,
the senior genetic counselor in M. D.
Anderson's Clinical Cancer Genetics
Program and a former consortium
coordinator and genetic counselor
at The University of Texas Health
Science Center at San Antonio.
Dr. Strong, who is the principal
investigator of the Texas research consor
tium, said that the group hopes
to recruit many more people who have
a strong family history of cancer (a single
type of cancer or multiple cancers within
the family) or who have had multiple
primary cancers or cancer at an unusually
early age. "Our goal is to develop an
extensive resource of patients with cancer,
survivors, and family members to serve
as study participants," said Or. Strong.
Network participants receive free
newsletters with the latest information
about genetic susceptibility to cancer
and have the opportunity to take part
in research studies, Dr. Strong said.
That research may be aimed at primary

prevention, chemoprevention, early
detection, or education about inherited
cancers, or it may involve more basic
research.
"Many people who are at high risk are
very eager to follow any new approaches
to early detection and prevention," Dr.
Strong said. Participating in the research
consortium's studies allows them to take
advantage of these new options. As for
the basic research studies, "Most people
who have an inherited predisposition to
cancer are very anxious that the body
of knowledge about this continues to
grow. Obviously, they have hope that
we'll have better information to offer
and better options for their children
and descendants than we may have
had for them or their parents," she said.
Most consortium participants are
recruited through a genetic counseling
and testing facility in their area. Once
someone joins the network, he or she
completes a questionnaire focusing on
personal and family history of cancer.
Some of the information from the
questionnaire is sent to the national
network-with no identifiers and
without revealing the participant's

name-and entered into a computer
database. Initially, participants might
only complete the questionnaire, or
they might also decide to take part in
research studies. They also agree co be
contacted about future research studies.
"We can offer network participants
genetic testing, counsel them about their
cancer risk, offer them recommendations
for management, and let them know
about any new information on their
particular condition," Dr. Strong said.
Most cancers result from random
genetic mutations that occur because a
mistake is made when cells are dividing or
in response to injuries from environmen
tal agents such as radiation or chemicals.
Inherited cancers, however, develop in
part from mutations carried in reproduc
tive cells. These mutations are· passed
on from one generation to the next and
are present in cells throughout the body.
People who inherit cancer are more likely
to develop the disease at a young age.
Genetic counselors assess the likeli
hood that the cancer in the participant's
family is hereditary and talk abouc
genetic testing, said Copeland. Evaluat
ing the patient's risk stares with con
structing a two- or three-generation
family pedigree. "Based on that, we
have a pretty good idea whether the
cancer is hereditary," she said.
About half of the people Copeland
counsels are reassured to learn that the
cancer in their family is not inherited.
If a person does have a family history
of hereditary cancer, Copeland discusses
the implications with the individual and
helps chem make an informed decision
about whether to proceed with genetic
testing.
"Only 5% to 10% of all cancers
are hereditary," Copeland said. "This
includes about 8% to 10% of colon
cancers, 5% to 7% of breast and ovarian
cancers, and less than 1 % of cervical
and lung cancers."
Genetic tests are not available for
all cancers. Some of the most common
genetic tests, said Copeland, detect a
person's predisposition to inherited
breast and ovarian cancers and to two
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